Systemic therapy in the management of metastatic or locally recurrent adenoid cystic carcinoma of the salivary glands: a systematic review
- PMID: 21147032
- DOI: 10.1016/S1470-2045(10)70245-X
Systemic therapy in the management of metastatic or locally recurrent adenoid cystic carcinoma of the salivary glands: a systematic review
Abstract
Adenoid cystic carcinomas (ACC) are rare cancers usually arising in the salivary glands. Once metastatic, the natural history can vary; some patients with indolent cancer remain asymptomatic for long periods, whereas others have rapidly progressive disease. Chemotherapy is generally reserved for the palliative treatment of symptomatic locally recurrent or metastatic disease that is not amenable to further surgery or radiation. Prospective trials of chemotherapy in advanced ACC are limited, and the optimum regimen is unclear. The aim of this systematic review is to summarise and rate the quality of trials assessing chemotherapy for treatment of ACC, by use of the European Lung Cancer Working Party scoring system. Endpoints evaluated include tumour response and rates of symptomatic improvement. 34 trials involving 441 patients are included. We give evidence-based recommendations for management of ACC with chemotherapy, along with considerations for the design of future clinical trials in this disease.
Copyright © 2011 Elsevier Ltd. All rights reserved.
Similar articles
-
Salivary gland adenoid cystic carcinoma: a review of chemotherapy and molecular therapies.Oral Oncol. 2006 Sep;42(8):759-69. doi: 10.1016/j.oraloncology.2006.01.001. Epub 2006 Jun 6. Oral Oncol. 2006. PMID: 16757203 Review.
-
Phase II study of cisplatin and imatinib in advanced salivary adenoid cystic carcinoma.Br J Oral Maxillofac Surg. 2011 Oct;49(7):510-5. doi: 10.1016/j.bjoms.2010.09.013. Epub 2010 Nov 10. Br J Oral Maxillofac Surg. 2011. PMID: 21071117 Clinical Trial.
-
Clinical trial of nintedanib in patients with recurrent or metastatic salivary gland cancer of the head and neck: A multicenter phase 2 study (Korean Cancer Study Group HN14-01).Cancer. 2017 Jun 1;123(11):1958-1964. doi: 10.1002/cncr.30537. Epub 2017 Jan 19. Cancer. 2017. PMID: 28102887 Clinical Trial.
-
Efficacy and toxicity of sorafenib in patients with adenoid cystic carcinoma of the head and neck: a case series of five patients.Acta Clin Belg. 2020 Oct;75(5):362-369. doi: 10.1080/17843286.2019.1633490. Epub 2019 Jun 23. Acta Clin Belg. 2020. PMID: 31232197
-
Systemic therapy in the management of metastatic or advanced salivary gland cancers.Oral Oncol. 2012 Oct;48(10):948-957. doi: 10.1016/j.oraloncology.2012.05.004. Epub 2012 Jun 12. Oral Oncol. 2012. Retraction in: Oral Oncol. 2018 Mar;78:229. doi: 10.1016/j.oraloncology.2018.01.034 PMID: 22698431 Retracted. Review.
Cited by
-
125I brachytherapy alone for recurrent or locally advanced adenoid cystic carcinoma of the oral and maxillofacial region.Strahlenther Onkol. 2013 Jun;189(6):502-7. doi: 10.1007/s00066-013-0324-3. Epub 2013 Apr 28. Strahlenther Onkol. 2013. PMID: 23625361
-
EGFR inhibition prevents in vitro tumor growth of salivary adenoid cystic carcinoma.BMC Cell Biol. 2013 Mar 9;14:13. doi: 10.1186/1471-2121-14-13. BMC Cell Biol. 2013. PMID: 23496982 Free PMC article.
-
Ongoing challenges in the treatment of adenoid cystic carcinoma of the head and neck.Ir J Med Sci. 2015 Sep;184(3):583-90. doi: 10.1007/s11845-015-1298-1. Epub 2015 Apr 17. Ir J Med Sci. 2015. PMID: 25894281 Review.
-
B-cell specific Moloney murine leukemia virus insertion site 1 contributes to invasion, metastasis, and poor prognosis in salivary adenoid cystic carcinoma.J Dent Sci. 2024 Jan;19(1):21-31. doi: 10.1016/j.jds.2023.06.014. Epub 2023 Jun 24. J Dent Sci. 2024. PMID: 38303897 Free PMC article.
-
Rare epithelial breast cancer: surgery and adjuvant therapy.Transl Cancer Res. 2019 Oct;8(Suppl 5):S479-S492. doi: 10.21037/tcr.2019.05.12. Transl Cancer Res. 2019. PMID: 35117126 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
